Cargando…

Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT

PURPOSE: The specific binding ratio (SBR) of (123)I-FP-CIT (FP-CIT) in the putamen decreases with age by about 5% per decade and most likely is about 10% higher in females. However, the clinical utility of age and sex correction of the SBR is still a matter of debate. This study tested the impact of...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitz-Steinkrüger, Helen, Lange, Catharina, Apostolova, Ivayla, Mathies, Franziska L., Frings, Lars, Klutmann, Susanne, Hellwig, Sabine, Meyer, Philipp T., Buchert, Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113204/
https://www.ncbi.nlm.nih.gov/pubmed/33130960
http://dx.doi.org/10.1007/s00259-020-05085-2
_version_ 1783690810204618752
author Schmitz-Steinkrüger, Helen
Lange, Catharina
Apostolova, Ivayla
Mathies, Franziska L.
Frings, Lars
Klutmann, Susanne
Hellwig, Sabine
Meyer, Philipp T.
Buchert, Ralph
author_facet Schmitz-Steinkrüger, Helen
Lange, Catharina
Apostolova, Ivayla
Mathies, Franziska L.
Frings, Lars
Klutmann, Susanne
Hellwig, Sabine
Meyer, Philipp T.
Buchert, Ralph
author_sort Schmitz-Steinkrüger, Helen
collection PubMed
description PURPOSE: The specific binding ratio (SBR) of (123)I-FP-CIT (FP-CIT) in the putamen decreases with age by about 5% per decade and most likely is about 10% higher in females. However, the clinical utility of age and sex correction of the SBR is still a matter of debate. This study tested the impact of age and sex correction on the diagnostic performance of the putamen SBR in three independent patient samples. METHODS: Research sample: 207 healthy controls (HC) and 438 Parkinson’s disease (PD) patients. Clinical sample A: 183 patients with neurodegenerative parkinsonian syndrome (PS) and 183 patients with non-neurodegenerative PS from one site. Clinical sample B: 84 patients with neurodegenerative PS and 38 patients with non-neurodegenerative PS from another site. Correction for age and sex of the putamen SBR was based on linear regression in the HC or non-neurodegenerative PS, separately in each sample. The area under the ROC curve (AUC) was used as performance measure. RESULTS: The putamen SBR was higher in females compared to males (PPMI: 14%, p < 0.0005; clinical sample A: 7%, p < 0.0005; clinical sample B: 6%, p = 0.361). Age-related decline of the putamen SBR ranged between 3.3 and 10.4% (p ≤ 0.019). In subjects ≥ 50 years, age and sex explained < 10% of SBR between-subjects variance. Correction of the putamen SBR for age and sex resulted in slightly decreased AUC in the PPMI sample (0.9955 versus 0.9969, p = 0.025) and in clinical sample A (0.9448 versus 0.9519, p = 0.057). There was a small, non-significant AUC increase in clinical sample B (0.9828 versus 0.9743, p = 0.232). CONCLUSION: These findings do not support age and sex correction of the putaminal FP-CIT SBR in the diagnostic workup of parkinsonian syndromes. This most likely is explained by the fact that the proportion of between-subjects variance caused by age and sex is considerably below the symptom threshold of about 50% reduction in neurodegenerative PS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-020-05085-2.
format Online
Article
Text
id pubmed-8113204
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-81132042021-05-13 Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT Schmitz-Steinkrüger, Helen Lange, Catharina Apostolova, Ivayla Mathies, Franziska L. Frings, Lars Klutmann, Susanne Hellwig, Sabine Meyer, Philipp T. Buchert, Ralph Eur J Nucl Med Mol Imaging Original Article PURPOSE: The specific binding ratio (SBR) of (123)I-FP-CIT (FP-CIT) in the putamen decreases with age by about 5% per decade and most likely is about 10% higher in females. However, the clinical utility of age and sex correction of the SBR is still a matter of debate. This study tested the impact of age and sex correction on the diagnostic performance of the putamen SBR in three independent patient samples. METHODS: Research sample: 207 healthy controls (HC) and 438 Parkinson’s disease (PD) patients. Clinical sample A: 183 patients with neurodegenerative parkinsonian syndrome (PS) and 183 patients with non-neurodegenerative PS from one site. Clinical sample B: 84 patients with neurodegenerative PS and 38 patients with non-neurodegenerative PS from another site. Correction for age and sex of the putamen SBR was based on linear regression in the HC or non-neurodegenerative PS, separately in each sample. The area under the ROC curve (AUC) was used as performance measure. RESULTS: The putamen SBR was higher in females compared to males (PPMI: 14%, p < 0.0005; clinical sample A: 7%, p < 0.0005; clinical sample B: 6%, p = 0.361). Age-related decline of the putamen SBR ranged between 3.3 and 10.4% (p ≤ 0.019). In subjects ≥ 50 years, age and sex explained < 10% of SBR between-subjects variance. Correction of the putamen SBR for age and sex resulted in slightly decreased AUC in the PPMI sample (0.9955 versus 0.9969, p = 0.025) and in clinical sample A (0.9448 versus 0.9519, p = 0.057). There was a small, non-significant AUC increase in clinical sample B (0.9828 versus 0.9743, p = 0.232). CONCLUSION: These findings do not support age and sex correction of the putaminal FP-CIT SBR in the diagnostic workup of parkinsonian syndromes. This most likely is explained by the fact that the proportion of between-subjects variance caused by age and sex is considerably below the symptom threshold of about 50% reduction in neurodegenerative PS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-020-05085-2. Springer Berlin Heidelberg 2020-10-31 2021 /pmc/articles/PMC8113204/ /pubmed/33130960 http://dx.doi.org/10.1007/s00259-020-05085-2 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Schmitz-Steinkrüger, Helen
Lange, Catharina
Apostolova, Ivayla
Mathies, Franziska L.
Frings, Lars
Klutmann, Susanne
Hellwig, Sabine
Meyer, Philipp T.
Buchert, Ralph
Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT
title Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT
title_full Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT
title_fullStr Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT
title_full_unstemmed Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT
title_short Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT
title_sort impact of age and sex correction on the diagnostic performance of dopamine transporter spect
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113204/
https://www.ncbi.nlm.nih.gov/pubmed/33130960
http://dx.doi.org/10.1007/s00259-020-05085-2
work_keys_str_mv AT schmitzsteinkrugerhelen impactofageandsexcorrectiononthediagnosticperformanceofdopaminetransporterspect
AT langecatharina impactofageandsexcorrectiononthediagnosticperformanceofdopaminetransporterspect
AT apostolovaivayla impactofageandsexcorrectiononthediagnosticperformanceofdopaminetransporterspect
AT mathiesfranziskal impactofageandsexcorrectiononthediagnosticperformanceofdopaminetransporterspect
AT fringslars impactofageandsexcorrectiononthediagnosticperformanceofdopaminetransporterspect
AT klutmannsusanne impactofageandsexcorrectiononthediagnosticperformanceofdopaminetransporterspect
AT hellwigsabine impactofageandsexcorrectiononthediagnosticperformanceofdopaminetransporterspect
AT meyerphilippt impactofageandsexcorrectiononthediagnosticperformanceofdopaminetransporterspect
AT buchertralph impactofageandsexcorrectiononthediagnosticperformanceofdopaminetransporterspect